| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.08 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.085 | 0.09 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.053 | 0.09 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.09 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.1 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |